检索结果-南通市图书馆

Efficacy and safety outcomes with remdesivir in COVID-19 patients:A meta-analysis

World Journal of Meta-Analysis 2021年第1期9卷 74-87页

作者： Tejas Kamleshbhai Patel Parvati B Patel manish barvaliya Vijayalaxmi Hira Lal Bhalla Department of Pharmacology All India Institute of Medical SciencesGorakhpurGorakhpur 273008Uttar PradeshIndia Department of Pharmacology GMERS Medical CollegeGotriVadodara 390021GujaratIndia Department of Pharmacology Government Medical CollegeBhavnagarBhavnagar 364001GujaratIndia

BACKGROUND Remdesivir is a broad-spectrum antiviral drug having in vitro activity against severe acute respiratory syndrome coronavirus 2 and is currently being used on a compassionate basis outside of clinical *** To analyze the efficacy and safety of remdesivir compared with other interventions in coronavirus disease 2019(COVID-19)*** We searched online databases to include randomized controlled trials evaluating the efficacy and safety of remdesivir compared with other interventions in COVID-19 *** summarized efficacy and safety data as risk ratios(RRs)with 95%confidence interval(CI)and used Mantel-Haenszel fixed or randomeffect *** estimated the number needed to treat(NNT)to cause one additional *** used the GRADE approach to assess the quality of the evidence for all outcome *** We included four randomized controlled *** observed no significant difference in mortality(RR:0.83;95%CI:0.57–1.20;I2=59%)and rate of ventilation(RR:0.69;95%CI:0.41-1.18;I2=77%)between remdesivir-and placebo-treated *** showed higher rates of clinical recovery than placebo(RR:1.10;95%CI:1.04–1.16;I2=0%;NNT:14.3).We observed no difference in overall adverse events between remdesivir-and placebo-treated patients(RR:1.05;95%CI:0.86–1.27;I2=77%).We observed less risk of serious adverse events(RR:0.75;95%CI:0.63–0.89;I2=0%)in remdesivir-than placebo-treated *** GRADE approach suggested moderate quality of evidence for all efficacy and safety *** We observed limited clinical benefit of remdesivir over placebo in the treatment of *** findings could be biased because of the small number of trials.

关键词： COVID-19 SARS-CoV-2 Antiviral Pneumonia Remdesivir Meta-analysis Systematic review

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：